RxDoctor Payments Data

Daniel Sterns, MD

Internal Medicine · Laguna Hillsq, CANPI 1083744643

Payments from drug & device makers

$3,665in general payments, 2019–2025

Across 202 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$621
  • Johnson & Johnson$338
  • AbbVie$288
  • Novo Nordisk$271
  • Amgen$258
  • Novartis$216
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,665 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$97,467
Medicare patients
261
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$68,154
OzempicSemaglutide47$52,271
JardianceEmpagliflozin36$35,193
MounjaroTirzepatide28$29,683
XareltoRivaroxaban18$27,388
LinzessLinaclotide20$18,746
FarxigaDapagliflozin Propanediol21$18,609
JanuviaSitagliptin Phosphate21$14,690
RybelsusSemaglutide13$12,698
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,404
Testosterone40$10,876
MyrbetriqMirabegron19$10,550
EntrestoSacubitril/Valsartan11$8,727
Breo ElliptaFluticasone/Vilanterol16$7,608
Levothyroxine Sodium339$5,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$68,15462 claims
Novo NordiskOzempic, Rybelsus$271$64,96960 claims
Boehringer IngelheimJardiance$42$35,19336 claims
Lilly USA, LLCMounjaro$41$29,68328 claims
Johnson & JohnsonXarelto$338$27,38818 claims
AbbVieLinzess, Synthroid$288$23,24788 claims
GSKTrelegy Ellipta, Breo Ellipta$118$20,01235 claims
AstraZenecaFarxiga$621$18,60921 claims
MerckJanuvia$185$14,69021 claims
Astellas Pharma US IncMyrbetriq$128$10,55019 claims
NovartisEntresto$216$8,72711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hillsq

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →